Halozyme Therapeutics Hits New 52-Week High at $109.65

Halozyme Therapeutics, Inc. has reached a significant milestone by hitting a new 52-week high of USD 109.65 on August 26, 2026. This achievement underscores the company's strong performance in the pharmaceuticals and biotechnology sector, where it operates as a small-cap entity with a market capitalization of USD 7,273 million. Over the past year, Halozyme has demonstrated impressive growth, with a remarkable 109.27% increase in its stock price, significantly outperforming the S&P 500, which recorded an 18.71% gain during the same period. The company's price-to-earnings (P/E) ratio stands at 11.00, indicating a favorable valuation relative to its earnings. Additionally, Halozyme's return on equity is exceptionally high at 1,371.85%, reflecting its efficient use of shareholder equity to generate profits. The stock's performance is further highlighted by its 52-week low of USD 61.23, showcasing the substantial upward movement in its price. As Halozyme Therapeutics continues to navigate the competitive landscape of the pharmaceuticals and biotechnology industry, this new high marks a noteworthy achievement in its financial journey.